Inactive Instrument

News RedHill Biopharma Ltd. OTC Markets

Equities

REDIF

IL0011223810

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

RedHill Biopharma Terminates License Agreement for Aemcolo	07-10	AQ
Redhill Biopharma Ltd. Terminates License Agreement for Aemcolo	07-09	CI
RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board	06-06	CI
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K	06-03	PU
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	05-06	MT
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K	05-06	PU
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035	05-06	PR
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	05-06	CI
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K	04-24	PU
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	04-24	CI
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights	04-09	AQ
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price	04-03	AQ
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023	03-27	CI
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	03-11	MT
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K	03-05	PU
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs	03-05	PR
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	03-05	CI
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication	02-21	AQ
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	02-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News RedHill Biopharma Ltd. OTC Markets

Equities

REDIF

IL0011223810

Summary

Filters